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ABSTRACT Early detection of insulin resistance (IR) or non-alcoholic fatty liver disease (NAFLD) is crucial to preventing fu-
ture risks of developing chronic diseases. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Liver Fat
Score (LFS), and Fatty Liver Index (FLI) are generally employed tomeasure severity stages of IR andNAFLD. The study of gene
expressions could explain themolecularmechanisms that occur early on in IR andNAFLD; thusprovidingpotential earlymark-
ers for both diseases. This studywas conducted to evaluate the gene expressions that could potentially be earlymarkers of IR
and NAFLD. All participants (n = 21) had normal blood glucose and were categorized as without hepatosteatosis (n = 10), at
higher risk of hepatosteatosis (n = 6), and hepatosteatosis (n = 5). Gene expression analysis was performed using the 2-∆∆CT
relative quantification method. There were significant differences in galnt2 (p < 0.002) and sirt1 (p < 0.010) expression be-
tween thefirst and the third tertiles ofHOMA-IR; and in ptpn1 (p <0.012) expression between thefirst and the second tertiles
of LFS. In conclusion, the expressions of galnt2 and sirt1 could be used as early markers of IR, while the expression of ptpn1
could be employed as an early marker of NAFLD.
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1. Introduction
Metabolic syndrome is a disorder of energy use and stor-
age. People with metabolic syndrome have an increased
risk of developing chronic diseases—such as type-2 dia-
betes mellitus (T2DM) and non-alcoholic fatty liver dis-
ease (NAFLD) (Mendrick et al. 2017), that lead to mor-
bidity and mortality (IDF 2005). According to the eighth
edition of Diabetes Atlas, a higher prevalence of diabetes
was observed in developing countries than in developed
countries. In 2017, there were 7.6 million people with un-
diagnosed diabetes, 10.3 million people (6.2% of the pop-
ulation) with diabetes, and 27.7 million people with im-
paired glucose tolerance (IGT) in Indonesia (IDF 2017).
In 2002, it was reported that about 30% of the population
in Indonesia was developing NAFLD (Hasan et al. 2002).
Type-2 diabetes mellitus and NAFLD do not develop
suddenly but are more likely caused by a prolonged un-
healthy lifestyle. These diseases can be prevented by
adopting a healthier lifestyle. Dietary patterns that are
high in glucose could eventually lead to hyperinsulinemia
and insulin resistance (Olokoba et al. 2012). Insulin re-
sistance is considered to play a role in the formation of
NAFLD due to abnormal fat metabolism in which hyper-
insulinemia triggers triglyceride synthesis and accumula-
tion in the liver. Non-alcoholic fatty liver disease is de-
fined as the accumulation of triglycerides >5% (steatosis)
in the liver of individuals who rarely consume alcoholic
beverages (Gaggini et al. 2013). In people with a normal
BMI, NAFLD is more commonly found in Asian popula-
tions and is referred to as a “metabolically obese” condi-
tion (Wong and Ahmed 2014). Therefore, the early detec-
tion of insulin resistance and NAFLD prior to diagnosis is
important to prevent the future risk of developing chronic
diseases (Preethi et al. 2011).
Some markers have been commonly used as clinical
measurement standards, such as the homeostatic model
assessment for insulin resistance (HOMA-IR) (Singh and
Saxena 2010) and the Liver Fat Score (LFS) (Kahl et al.
2014) and the Fatty Liver Index (FLI) for fatty liver dis-
ease (Du et al. 2014). These markers are widely em-
ployed to diagnose and categorize developed stages of in-
sulin resistance or NAFLD. For example, tertile analysis
of HOMA-IR shows an association with glycemic control
in the lean, non-diabetic Asian population (Hirata et al.
2015). However, these markers could not explain the
molecular mechanism underlying the early conditions of
insulin resistance and NAFLD.
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TABLE 1 Formulas to calculate the indices.
Indices Formula Citation
HOMA-IR = (FPI [mIU/L]× FPG (mmol/L)/22.5 Singh and Saxena (2010)
LFS = −2.89+ 1.18×MetS (yes=1/no=0)+ 0.45× T2D (yes=2/no=0)+ 0.15× FPI (mIU/L)+
0.04× AST (IU/L) 0.94× AST/ALT
Kahl et al. (2014)
FLI = (e0.953× loge (TG)+ 0.139× BMI+ 0.718× loge (GGT)+ 0.053×WC− 15.745) / (1 +
e0.953×loge (TG)+ 0.139× BMI+ 0.718× loge (GGT)+ 0.053×WC− 15.745)× 100
Du et al. (2014)
Allbloodparametersusedshouldbecollectedaftera10–12hovernight fast. ALT:alanineaminotransferase;AST:aspartateaminotransferase;
BMI:bodymass index; FPG: fastingplasmaglucose; FPI: fastingplasma insulin;GGT:gamma-glutamyl transferase;MetS:metabolic syndrome;
TG: triglyceride; T2D: Type-2-Diabetes;WC: waist circumference;WHR: waist-hip ratio.
Several genes are known to be involved in the develop-
ment of insulin resistance; thus, they could be employed
as potential molecular markers for insulin resistance. The
relevant genes are galnt2, sirt1, and ptpn1. The expression
of galnt2, a gene that encodes N-acetylgalactosaminyl-
transferase, could decrease the expression of enpp1, which
encodes the inhibitor protein involved in insulin receptor
signaling (inhibits insulin and insulin receptor (IR) inter-
action) (Marucci et al. 2013a). The genes sirt1 and ptpn1
have been studied for their role in the development of in-
sulin resistance. The ptpn1 gene encodes protein tyrosine
phosphatase 1B (PTP1B), a protein that could catalyze de-
phosphorilation of IR and insulin receptor substrates (IRS)
tyrosine residues, and cause a disturbance of the insulin
signaling pathway (Stull et al. 2012). Sirtuin 1 was in-
volved in the deacetylation of PTP1B, which further de-
activates PTP1B as a negative regulator of insulin, and
was able to improve insulin sensitivity under conditions
of insulin resistance (Sun et al. 2007). Thus, this study
evaluates the gene expression of galnt2, sirt1, and ptpn1,
which could potentially be early markers of insulin resis-
tance and NAFLD in the Indonesian population.
2. Materials andmethods
Study participants were selected from employees of PT
Nutrifood Indonesia. A total of 21 participants consisting
of 10 men and 11 women were involved in this study. In-
clusion criteria included healthy adults aged 23–40 years,
with a fasting blood glucose <100 mg/dL, no history of
hepatitis, and not smoking, pregnant or breastfeeding.
Subjects were asked to sign a medical action agreement,
and they underwent anthropometric and blood biochemi-
cal parameters testing according to ethical clearance ap-
proved by Research Ethics Commission of UNIKA Atma
Jaya. The anthropometric parametersmeasuredwere body
mass index (BMI), visceral fat area, waist circumference,
and hip circumference. Body composition was measured
using InBody 230 (Biospace) according to the tool proto-
cols. For fasting blood sampling, subjects were asked to
fast for 10–12 h (overnight). The blood biochemical pa-
rameters (other than fasting insulin) were measured using
a commercial laboratory service (Prodia). The values of
HOMA-IR, LFS, and FLI were calculated using the for-
mulas presented in Table 1. Fasting insulin was measured
using Ultrasensitive Insulin ELISA (Mercodia).
The isolation of RNA from fasting blood samples was
performed using a QIAamp® RNA Blood Mini Kit (Qi-
agen). The concentration and purity of RNA were mea-
sured with a NanoDrop2000 (Thermo Fisher Scientific).
The cDNA synthesis was performed using a RevertAid
First Strand cDNA Synthesis Kit (Thermo Fisher Scien-
tific) on PCR GS482 (G-Storm). The cDNA synthesis
results were then used to measure gene expression. The
gene expression was quantified by using a StepReePlus
Real-Time PCR System (Thermo Fisher Scientific). The
reaction was carried out under the following conditions:
pre-denaturation at 95°C for 2 min; denaturation at 95°C
for 20 s; primer annealing for 40 s with the suitable tem-
peratures: 55°C (for actb and galnt2), 60°C (for sirt1),
and 62°C (for ptpn1); and fluorescent acquisition at 72°C
for 30 s; with a total of 40× qPCR cycles. The ex-
pression level analysis was performed using the 2-∆∆CT
relative quantification method, using the expression of
actb as a reference to normalize the gene expression level
of target genes (Livak and Schmittgen 2001). The for-
ward and reverse primers used for qPCR were: actb (5’-
TCCCTGGAGAAGAGCTACGA-3’ and 5’-ATCTGCT-
TABLE 2 Study participants’ characteristics as mean (± SD).
Characteristics All (n = 21) SEM Kolgomorov-
Smirnov
Age (years) 30.52 (±5.32) 1.16 ns
Triglycerides (mg/dL) 93.48 (±43.22) 9.43 ns
Glucose (mg/dL) 82.29 (±9.71) 2.12 ∗
Insulin (mIU/L) 8.50 (±6.91) 1.51 ‡
AST (IU/L) 28.31 (±11.62) 2.54 ∗
ALT (IU/L) 33.28 (±28.48) 6.21 †
GGT (IU/L) 25.00 (±16.26) 3.55 ∗
WC (cm) 89.90 (±9.09) 1.98 ns
WHR 0.89 (±0.05) 0.01 ns
BMI 26.10 (±3.51) 0.76 ns
HDL (mg/dL) 46.95 (±7.50) 1.63 ns
∗ p < 0.05; † p < 0.01; ‡ p < 0.001 SEM: Standard error means. All
blood parameters were collected after a 10–12 h overnight fast.
ALT: alanine aminotransferase; AST: aspartate aminotransferase;
BMI: body mass index; GGT: gamma-glutamyl transferase; HDL:
high-density lipoprotein; WC: waist circumference; WHR: waist-
hip ratio.
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3’ and 5’-TCCTAGGtTGCCCAGCTGATGAA-3’); and
ptpn1 (5’-TGGGTGAAGGAAGAGACCCA-3’ and 5’-
CCCACGACCCGACTTCTAAC-3’).
The collected data were statistically analyzed using
SPSS Statistics 22 (IBM, Armonk, New York, United
States). Normality, outlier, and descriptive analyses were
performed for each fasting blood biochemical parameter
and index and for gene expression. For the gene expres-
sion analysis, HOMA-IR, LFS, and FLI were sorted from
the lowest value to the highest value and were divided into
tertiles. Statistical analysis was performed among tertiles
of referred indices, in which this method of tertile analysis
could be used to evaluate associations of markers (Hirata
et al. 2015). An independent T-Test mean difference was
performed on the expression of galnt2, sirt1, and ptpn1
between tertiles of HOMA-IR, LFS, and FLI.
3. Results and discussion
Characteristics of all study participants are presented in Ta-
ble 2. All study participants were normoglycemic (FPG
<100 mg/dL). Normality and outlier analysis resulted in
validHOMA-IR values for further analysis (n = 18) ranged
from 0.45–2.20, LFS (n = 20) ranged from −3.99–0.71,
and FLI (n = 21) ranged from 3.40–83.21. Two partici-
pants were categorized as insulin resistant based on the cut-
off value of HOMA-IR ≥ 2.04 for the diagnosis of insulin
resistance in Indonesia (Purnamasari et al. 2010). Thir-
teen participants were categorized as non-NAFLD, three
participants were estimated to have elevated liver fat, four
participants were predicted to have NAFLD, and no partic-
ipants were diagnosed with NAFLD, based on the cut-off
values of LFS < −1.413 to exclude NAFLD, LFS > −0.640
to predict NAFLD, and LFS > 1,257 to diagnose NAFLD
(Kotronen et al. 2009). Ten participants were categorized
without hepatosteatosis, six participants were identified as
having a higher risk of hepatosteatosis, and five partici-
pants were characterized as having hepatosteatosis, based
on the cut-off values of FLI < 30 to exclude NAFLD and
FLI ≥ 60 to diagnose hepatosteatosis (Bedogni et al. 2006).
Based on the U.S. National Cholesterol Education
Program Adult Treatment Panel III (NCEP ATP III), the
triglyceride concentrations of our study population (52-
242 mg/dL) were classified as normal to high (NCEP
2001). The study population levels of GGT andHDLwere
categorized as normal. Increased ALT levels in some par-
ticipants might occur once in a while, intermittently, or be
caused by steatohepatitis (Aragon and Younossi 2010).
The HOMA-IR, LFS, and FLI values were divided
into tertiles. The lowest values are the first tertile (T1), and
the highest values are the third tertile (T3). Analyses of
study participants’ characteristics relative to HOMA-IR,
LFS, and FLI are presented in Table 3, 4, and 5, respec-
tively. An analysis of gene expression among each tertile
group is presented in Table 6.
There were significant mean differences between ter-
tiles of HOMA-IR for TG (T1–T2), insulin (T1–T2, T2–
T3, T1–T3),WC (T2–T3, T1–T3),WHR (T2–T3, T1–T3),
and BMI (T2–T3) (Table 3). These suggest that the an-
thropometric parameters of WC, WHR, and BMI strongly
influence the glycemic response and might be interpreted
as early signs of insulin resistance in normoglycemic sub-
jects. There were significant mean differences between
tertiles of LFS for fasting glucose (T1–T3), insulin (T1–
T2, T1–T3), ALT (T2–T3, T1–T3), GGT (T1–T2, T2–T3,
T1–T3), WC (T1–T2, T1–T3), WHR (T1–T3), and HDL
(T2–T3) (Table 4). There were significant mean differ-
TABLE 3 Tertiles of HOMA-IR.
Characteristics T1 (n = 6) T2 (n = 6) T3 (n = 6) p
T1 vs. T2 T2 vs. T3 T1 vs. T3
Age (years) 30.17 (±5.46) 34.00 (±4.90) 29.00 (±5.80) ns ns ns
Triglycerides (mg/dL) 65.17 (±12.25) 93.00 (±25.67) 94.33 (±30.61) ∗ ns ns
Glucose (mg/dL) 77.83 (±2.93) 78.67 (±4.84) 84.84 (±7.19) ns ns ns
Insulin (mIU/L) 3.54 (±0.84) 5.56 (±0.62) 8.81 (±1.19) † ‡ ‡
AST (IU/L) 23.83 (±4.26) 31.00 (±12.33) 32.50 (±17.57) ns ns ns
ALT (IU/L) 20.00 (±10.73) 38.33 (±34.89) 43.83 (±38.32) ns ns ns
GGT (IU/L) 14.67 (±5.20) 21.67 (±15.91) 32.50 (±18.31) ns ns ns
WC (cm) 82.17 (±5.49) 85.67 (±4.68) 97.00 (±3.85) ns † ‡
WHR 0.86 (±0.04) 0.87 (±0.04) 0.93 (±0.04) ns ∗ †
BMI 24.03 (±3.79) 24.87 (±2.11) 28.30 (±3.06) ns ∗ ns
HDL (mg/dL) 47.00 (±5.51) 50.17 (±8.40) 47.33 (±6.80) ns ns ns
HOMA-IR 0.68 (±0.17) 1.08 (±0.16) 1.85 (±0.33) † † ‡
∗ p < 0.05; † p < 0.01; ‡ p < 0.001. All blood parameters were collected after a 10-12 h overnight fast. ALT: alanine aminotransferase; AST:
aspartate aminotransferase; BMI: body mass index; GGT: gamma-glutamyl transferase; HDL: high-density lipoprotein; WC: waist circumfer-
ence;WHR: waist-hip ratio.
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TABLE 4 Tertiles of LFS.
Characteristics T1 (n = 7) T2 (n = 6) T3 (n = 7) p
T1 vs. T2 T2 vs. T3 T1 vs. T3
Age (years) 33.14 (±5.55) 30.00 (±7.16) 29.00 (±2.52) ns ns ns
Triglycerides (mg/dL) 64.86 (±12.75) 96.33 (±31.85) 114.29 (±59.28) ns ns ns
Glucose (mg/dL) 76.29 (±3.25) 81.33 (±5.61) 89.71 (±12.93) ns ns ∗
Insulin (mIU/L) 3.93 (±1.15) 6.53 (±2.16) 11.75 (±6.33) ∗ ns ∗
AST (IU/L) 23.57 (±5.74) 24.83 (±5.15) 38.00 (±15.70) ns ns ns
ALT (IU/L) 16.43 (±7.76) 24.33 (±9.05) 59.71 (±36.32) ns ∗ ∗
GGT (IU/L) 12.00 (±4.51) 18.00 (±3.74) 43.57 (±14.11) ∗ † †
WC (cm) 82.29 (±5.12) 92.67 (±8.66) 92.71 (±8.81) ∗ ns ∗
WHR 0.85 (±0.03) 0.90 (±0.04) 0.91 (±0.05) ns ns ∗
BMI 24.07 (±3.48) 26.90 (±3.87) 27.10 (±2.96) ns ns ns
HDL (mg/dL) 51.71 (±6.90) 47.50 (±6.92) 41.29 (±5.77) ns ns ∗
LFS −2.92 (±0.60) −1.95 (±0.26) −0.27 (±0.84) † † ‡
∗ p < 0.05; † p < 0.01; ‡ p < 0.001. All blood parameters were collected after a 10–12 h overnight fast. ALT: alanine aminotransferase; AST:
aspartate aminotransferase; BMI: body mass index; GGT: gamma-glutamyl transferase; HDL: high-density lipoprotein; WC: waist circumfer-
ence;WHR: waist-hip ratio.
ences between tertiles of FLI for age (T2–T3), TG (T1–
T3), insulin (T2–T3, T1–T3), GGT (T1–T3), WC (T2–T3,
T1–T3), WHR (T1–T3), BMI (T1–T2, T1–T3), and HDL
(T2–T3) (Table 5). The elevation of AST, ALT, and GGT,
which are liver-produced enzymes, usually indicates liver
damage, which can also be caused by NAFLD (Aragon
and Younossi 2010). Increased insulin levels in partici-
pants with normal glucose levels, along with the increased
risk of NAFLD, suggest an association between IR and
NAFLD, even at its earliest stages. Significant differences
observed for WC, WHR, and BMI also confirm that these
anthropometric parameters play a role in developing early
insulin resistance and further contribute to the develop-
ment of NAFLD.
There were significant mean differences of galnt2 (p
< 0.002) and sirt1(p < 0.010) expression between the first
tertile (T1) and the third tertile (T3) of HOMA-IR. Accord-
ing to study participants’ characteristics among tertiles of
HOMA-IR, there was a significant difference in fasting
insulin among tertiles, but there was no significant differ-
ence in fasting glucose (Table 3). This result indicates that
although T3 of HOMA-IR was categorized as insulin sen-
sitive due to its normal glucose level, it was somewhat
closer to insulin resistance condition than T1. Therefore,
T3 of HOMA-IR can be referred to as the early condition
of insulin resistance (Preethi et al. 2011). These results
suggest that galnt2 and sirt1 expression can be used as
markers of the early condition of insulin resistance.
The significant difference in galnt2 expression be-
tween the first and the third tertiles of HOMA-IR indicates
that an increasing value of HOMA-IR in normoglycemic
participants was followed by the increased expression of
galnt2 (Table 6). This result seems to be contradictory
to the previous study by Marucci et al. (2013b), which
demonstrated that galnt2 mRNA expression levels in pe-
ripheral whole blood cells were significantly reduced from
control to obese to diabetics. In-vitro study in human
monocytes had identified hyperglycemia as a major cause
of galnt2 down-regulation in patients with T2D (Marucci
et al. 2013b). Our study population had a wide range of
fasting insulin levels, but they were still categorized as
normoglycemic (fasting glucose level <100 mg/dL); thus,
the expression of galnt2 was not expected to be heteroge-
neous among the subjects. Interestingly, in the T3 group,
where insulin resistance levels were higher, the expression
of galnt2 was higher than in the T1 group. This condition
was might be due to in the early condition of insulin resis-
tance, galnt2 would be expressed higher to inhibit enpp1,
an inhibitor for insulin signaling (Marucci et al. 2013b),
thus, enabling the insulin to work optimally. This result
suggests that galnt2 could be a molecular marker for the
early development of insulin resistance.
The significant difference in sirt1 expression between
the first and the third tertiles of HOMA-IR also indicate
that the increasing value of HOMA-IR is associated with
a significantly higher expression of sirt1 (Table 6). This
result seems to be contradictory with the previous study
by Song et al. (2011) that demonstrated that sirt1 mRNA
expression levels in the T2DM group were lower com-
pared with the healthy group. SIRT1 deacetylase activity
consumes NAD+, and a high blood sugar level in T2DM
patients will decrease the NAD+/NADH ratio. The de-
crease of NAD+/NADH caused by altered homeostasis of
glucose metabolism will be followed by a subsequent de-
crease of sirt1 expression (Kitada and Koya 2013). There-
fore, as for galnt2, a hyperglycemia might also be the
cause of sirt1 down-regulation in patients with T2D. Our
study population had a wide range of fasting insulin levels,
but they were still categorized as normoglycemic (fasting
glucose level <100 mg/dL); thus, the expression of sirt1
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was not supposed to be heterogeneous among the subjects.
Instead, our study illustrates that a higher fasting plasma
insulin (T3) within the normoglycemic population is as-
sociated with increased sirt1 expression. This result is
in accordance with SIRT1’s positive role in the insulin-
signaling pathway by inducing insulin secretion, in which
SIRT1 activation increases glucose uptake and insulin sig-
naling (Song et al. 2011). In the early condition of insulin
resistance, sirt1 would be expressed higher to induce in-
sulin secretion until the body was unable to maintain nor-
mal blood sugar homeostasis, after which the expression
of sirt1 would drop. Thus, sirt1 could be a molecular
marker of the early development of insulin resistance.
There was no significant mean difference in ptpn1 ex-
pression across the tertiles of HOMA-IR. This result prob-
ably showed that ptpn1 expression would be up-regulated
in the later stage of insulin resistance (Stull et al. 2012),
and not in the early condition of insulin resistance. In
this study, a difference of ptpn1 expression (p < 0.012)
was only observed between the first and the second tertile
of LFS, where the second tertile was significantly higher
than the first tertile. Higher expression in T2 than in
T1 in this study was in accordance with another report
that found ptpn1 to be up-regulated in liver biopsies of
Non-Alcoholic SteatoHepatitis (NASH) patients (Sander-
son and Smyrk 2005). Higher expression of ptpn1 could
also be caused by hepatocyte inflammation of TNF-α, as
reported in the previous study of hepatocyte inflamma-
tion in vitro (Zabolotny et al. 2008). Therefore, these re-
sults suggest that changes in ptpn1 expression (which is
a protein tyrosine kinase) in blood might also be studied
as molecular markers for the early stages of NAFLD. No
TABLE 5 Tertiles of FLI.
Characteristics T1 (n = 7) T2 (n = 7) T3 (n = 7) p
T1 vs. T2 T2 vs. T3 T1 vs. T3
Age (years) 32.29 (±6.34) 32.86 (±4.14) 26.43 (±2.70) ns † ns
Triglycerides (mg/dL) 65.14 (±12.55) 89.00 (±25.87) 126.29 (±56.42) ns ns ∗
Glucose (mg/dL) 78.71 (±5.71) 81.43 (±6.16) 86.71 (±14.33) ns ns ns
Insulin (mIU/L) 5.18 (±2.27) 5.32 (±2.19) 15.00 (±8.69) ns ∗ ∗
AST (IU/L) 24.43 (±6.37) 30.57 (±10.39) 31.43 (±16.36) ns ns ns
ALT (IU/L) 17.00 (±9.59) 41.43 (±30.30) 41.43 (±35.06) ns ns ns
GGT (IU/L) 13.29 (±5.28) 24.71 (±13.60) 37.00 (±13.44) ns ns ∗
WC (cm) 82.29 (±6.18) 88.29 (±4.07) 99.14 (±7.10) ns † ‡
WHR 0.85 (±0.03) 0.88 (±0.03) 0.92 (±0.05) ns ns †
BMI 22.86 (±1.93) 26.34 (±2.62) 29.11 (±2.73) ∗ ns ‡
HDL (mg/dL) 53.29 (±7.85) 44.57 (±3.46) 43.00 (±6.43) ∗ ns ∗
FLI 9.28 (±5.00) 29.03 (±12.27) 63.97 (±11.40) † ‡ ‡
∗ p < 0.05; † p < 0.01; ‡ p < 0.001. All blood parameters were collected after a 10–12 h overnight fast. ALT: alanine aminotransferase; AST:
aspartate aminotransferase; BMI: body mass index; GGT: gamma-glutamyl transferase; HDL: high-density lipoprotein; WC: waist circumfer-
ence;WHR: waist-hip ratio.
TABLE 6 Expression of galnt2, sirt1, and ptpn1 (mean ± SD) between tertiles of HOMA-IR, LFS, and FLI.
Index Gene T1 T2 T3 p
T1 vs. T2 T2 vs. T3 T1 vs. T3
HOMA-IR galnt2 0.66 (±0.08) 0.71 (±0.32) 0.90 (±0.12) ns ns †
sirt1 0.74 (±0.05) 0.84 (±0.20) 0.92 (±0.12) ns ns ∗
ptpn1 0.89 (±0.13) 0.84 (±0.29) 1.06 (±0.15) ns ns ns
LFS galnt2 0.68 (±0.16) 0.86 (±0.13) 0.78 (±0.32) ns ns ns
sirt1 0.78 (±0.12) 0.88 (±0.15) 0.85 (±0.24) ns ns ns
ptpn1 0.83 (±0.15) 1.07 (±0.13) 0.90 (±0.28) ∗ ns ns
FLI galnt2 0.74 (±0.16) 0.62 (±0.27) 0.88 (±0.17) ns ns ns
sirt1 0.80 (±0.15) 0.79 (±0.18) 0.91 (±0.18) ns ns ns
ptpn1 0.89 (±0.17) 0.84 (±0.27) 0.97 (±0.14) ns ns ns
Independent sample t-test. ∗ p < 0.05; † p < 0.01; ‡ p < 0.001. The expression level analysis was performed using the expression ofactb as a
reference to normalize gene expression level of target genes.
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significant mean difference in galnt2 and sirt1 expression
among tertiles of LFS and FLI was found.
This study was designed as a preliminary study, in
which researchers were aware of the limitations of using
a relatively small number of participants. However, this
study provides insight for further exploration of poten-
tial markers for the early stages of insulin resistance and
NAFLD in healthy individuals.
4. Conclusions
Further study is needed for galnt2 and sirt1 expression as
potential molecular markers for the early stages of insulin
resistance in a larger population. And although ptpn1 ex-
pression was not correlated with early insulin resistance,
ptpn1 expression could be studied further as a molecular
marker for early non-alcoholic fatty liver disease.
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